Sung Ji Nam
Stock Analyst at Scotiabank
(3.58)
# 861
Out of 5,124 analysts
83
Total ratings
50.72%
Success rate
6.9%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $102.14 | -41.26% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $58.81 | +27.53% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $228.92 | +20.13% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $579.45 | +1.82% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $131.16 | -4.70% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $38.90 | +2.83% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $6.80 | +488.24% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $6.15 | -2.44% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.53 | +161.44% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.87 | +6.95% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $101.56 | -28.12% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $16.24 | -26.11% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $379.83 | +18.47% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $31.72 | +95.46% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $42.10 | +4.51% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $18.84 | +85.77% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $3.80 | +57.89% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.27 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $102.14
Upside: -41.26%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $58.81
Upside: +27.53%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $228.92
Upside: +20.13%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $579.45
Upside: +1.82%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $131.16
Upside: -4.70%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $38.90
Upside: +2.83%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $6.80
Upside: +488.24%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $6.15
Upside: -2.44%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.53
Upside: +161.44%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.87
Upside: +6.95%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $101.56
Upside: -28.12%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $16.24
Upside: -26.11%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $379.83
Upside: +18.47%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $31.72
Upside: +95.46%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $42.10
Upside: +4.51%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $18.84
Upside: +85.77%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $3.80
Upside: +57.89%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $26.27
Upside: -